SurgiBox Inc discloses $486,000 raised in Regulation D offering
The Cambridge, Massachusetts biotechnology company reported a $3,000,000 target offering with 9 investors participating as of the filing date.
SurgiBox Inc, a Delaware corporation based in Cambridge, Massachusetts, filed a Form D with the Securities and Exchange Commission disclosing details of an exempt securities offering. The filing lists the date of first sale as March 19, 2026, under a new notice type of filing.1
The total offering amount was set at $3,000,000, with $486,000 already sold and $2,514,000 remaining to be sold.1 The company reported a total of 9 investors who had already invested in the offering.1
The offering claims exemption under Rule 506(b).1 The types of securities offered include a security to be acquired upon exercise of an option, warrant, or other right to acquire a security, as well as another category described as a Simple Agreement for Future Equity.1
The company indicated it does not intend for the offering to last more than one year.1 The minimum investment accepted from any outside investor was listed as $0.1
The filing reported no sales commissions or finders' fees associated with the offering.1 SurgiBox declined to disclose its revenue range or aggregate net asset value range.1
Among the related persons named in the filing, Laurel Kelly is listed with a c/o SurgiBox Inc address in Cambridge, Massachusetts, and is identified with the relationship of both Executive Officer and Director.1 Other related persons named as directors include Sam Goldberger, Steve Eppinger, Mike Teodorescu, and Debbie Teodorescu.
The filing classifies the issuer's industry group as Biotechnology within the Health Care category.1 The notice was signed by Peter Cifichiello, identified as Account Administrator, on March 19, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.